Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

Study:

Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused By Ragweed Pollen

Rationale:

n/a

Purpose:

The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Allergic Rhinitis Biological: Ragweed Allergenic Extract Immunotherapy
Biological: Ragweed allergenic extract		 Phase 3

Verified by Greer Laboratories June, 2008

Sponsored by: Greer Laboratories
Information provided by: Greer Laboratories
ClinicalTrials.gov identifier: NCT00599872

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.